advaxis
announces
fda
clearance
new
ind
treatment
prostate
cancer
strategic
transition
investigator
sponsored
ind
previously
announced
advaxis
sponsored
ind
initiation
investigator
sponsored
phase
study
prostate
cancer
princeton
globe
newswire
advaxis
nasdaq
adxs
biotechnology
company
focused
development
commercialization
immunotherapy
products
today
announced
food
drug
administration
fda
cleared
new
investigational
new
drug
ind
application
initiation
investigator
sponsored
phase
clinical
study
company
neoantigen
candidate
prostate
cancer
new
ind
addition
advaxis
sponsored
ind
previously
announced
january
advaxis
intends
first
advance
clinical
evaluation
investigator
sponsored
phase
study
prostate
cancer
patients
biochemical
recurrence
remains
initiation
fourth
quarter
year
excited
announce
transition
hot
prostate
program
investigator
sponsored
study
time
said
kenneth
berlin
president
chief
executive
officer
advaxis
partnering
prestigious
academic
medical
center
would
gaining
access
expertise
high
volume
patients
together
may
expedite
enrollment
eventual
study
results
strategic
decision
also
conserves
resources
leveraged
support
encouraging
expanding
hot
program
nsclc
data
generated
date
nsclc
leave
us
increasingly
confident
neoantigen
program
provide
treatments
robust
innate
adaptive
immune
responses
potential
clinical
activity
look
forward
initiation
phase
study
monotherapy
patients
prostate
cancer
year
advaxis
advaxis
biotechnology
company
focused
development
commercialization
proprietary
antigen
delivery
products
immunotherapies
based
platform
technology
utilizes
live
attenuated
listeria
monocytogenes
lm
bioengineered
secrete
antigen
adjuvant
fusion
proteins
strains
believed
significant
advancement
immunotherapy
integrate
multiple
functions
single
immunotherapy
designed
access
direct
antigen
presenting
cells
stimulate
cell
immunity
activate
immune
system
equivalent
multiple
adjuvants
simultaneously
reduce
tumor
protection
tumor
microenvironment
enable
cells
eliminate
tumors
learn
advaxis
visit
connect
twitter
linkedin
facebook
youtube
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
statements
express
current
beliefs
expectations
management
including
limited
statements
related
expected
clinical
development
company
drug
product
candidates
risks
discussed
company
filings
sec
including
without
limitation
annual
report
form
filed
december
form
february
periodic
reports
form
form
statements
contained
herein
describe
historical
facts
statements
subject
risks
uncertainties
could
cause
actual
results
performance
achievements
differ
materially
discussed
statements
company
cautions
readers
place
undue
reliance
statements
speak
date
made
company
undertakes
obligation
update
revise
statements
except
otherwise
required
law
whether
result
new
information
future
events
otherwise
contact
tim
mccarthy
lifesci
advisors
llc
tim
